Rothschild Redburn downgrades Moderna stock on valuation concerns
Covered in this story
What has happened since
- Moderna is up 47.6% since this was published, 36 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Rothschild & Co Redburn’s $81 target on $MRNA is on the record and being tracked to Sep 2027 (12-month default), scored on the close that day.
Rothschild & Co Redburn’s track record →Analyst targets on Moderna
- Citi: $193 → $80 by Sep 2027 · Sell via 247wallst.com
- Morgan Stanley: $174 → $89 by Aug 2027 · Equalweight via Investing.com
- Bank of America: $174 → $170 by Aug 2027 · Neutral via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Moderna →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.